Press Releases
| Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering Mar 10, 2025
Philadelphia, Pennsylvania--(Newsfile Corp. - March 10, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced Tier II Regulation A offering of 1,490,000 units, on a "best-efforts" basis, at a price of $2.80 pe... |
| Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering Mar 6, 2025
Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its Tier II Regulation A offering of 1,490,000 units, on a "best-efforts" basis, at a price of $2.80 per unit. Each unit cons... |
| Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) Mar 6, 2025
The Interim Analysis Showed Complete Clinical Clearance of More Than Sixty (60%) PercentPHILADELPHIA, March 06, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce a positively tre... |
| Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) Feb 27, 2025
The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAEPHILADELPHIA, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Comp... |
| Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) Feb 14, 2025
The company is on track to complete the interim data analysis before the end of Q1 2025 and to submit the findings to the U.S. Food And Drug Administration (FDA)PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MD... |
| Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV) Feb 11, 2025
Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital MarketToronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") today announced that it has entered into a... |
| Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV) Feb 11, 2025
Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital MarketTORONTO and PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") today announced that it has entered int... |
| Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch Dec 12, 2024
Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in HorsesTORONTO and PHILADELPHIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is ... |
| Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region Dec 2, 2024
Provides Update on SKNJCT-003 Phase 2 Clinical Study for Treatment of Nodular Basal Cell Carcinoma (BCC) Currently Underway in United StatesTORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus... |
| Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer Nov 18, 2024
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D ProgramTORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ: MDCX TSXV: MDCX) (the "Company") is pleased to announce the appoi... |